Parameswaran Hari

Company: Obsidian Therapeutics

Job title: Chief Development Officer

Bio:

Parameswaran Hari, M.D., M.S., is Obsidian’s Chief Development Officer. Dr. Hari brings decades of experience designing, managing and leading complex cell and gene therapy clinical programs, including TIL therapies. Previously, Dr. Hari was Senior Vice President, Clinical Science at Iovance Biotherapeutics, where he led solid tumor adoptive cell therapy programs across multiple tumor types and indications, including new IND submission, first in human phase 1 studies and BLA submission efforts. Prior to Iovance, Dr. Hari was the Chief of Hematology and Oncology at the Medical College of Wisconsin, where he led national cooperative multi-PI trial groups in cell and gene therapy and multiple myeloma. He also served the American Society of Transplantation and Cellular Therapy (ASTCT) as its secretary. Dr. Hari received his M.B.B.S at Kerala University, M.D. at Central University of Pondicherry, and his M.S. at the Medical College of Wisconsin.

Seminars:

OBX-115 Engineered TIL with Regulatable Membrane- Bound IL15: Translational Data from Patients with Advanced Melanoma 12:00 pm

OBX-115 is a highly differentiated TIL cell therapy with optimized characteristics for response and persistence This data confirms successful platform validation, supporting the proposed OBX-115 mechanism of action ACZ dose-driven regulatable mbIL15 expression on OBX-115 enables elimination of IL2 from the regimen and the potential for a safer, more effective TIL cell therapyRead more

day: Conference Day One CMC Track AM